Migalastat treatment in a kidney-transplanted patient with fabry disease and n215s mutation: The first case report

Valeria Di Stefano, Marta Mancarella, Antonia Camporeale, Anna Regalia, Marta Ferraresi, Marco Pisaniello, Elena Cassinerio, Federico Pieruzzi, Irene Motta

Research output: Contribution to journalArticlepeer-review

Abstract

Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to deficient α-galactosidase A activity and, consequently, to glycosphingolipid accumulation in a wide variety of cells. Fabry disease due to N215S (c.644A>G, p.Asn215Ser) missense mutation usually results in a late-onset phenotype presenting with isolated cardiac involvement. We herein present the case of a patient with N215S mutation with cardiac involvement, namely left ventricular hypertrophy and ventricular arrhythmias, and end-stage renal disease requiring kidney transplantation. To the best of our knowledge, this is the first report of a kidney-transplanted Fabry patient treated with oral pharmacologic chaperone migalastat.

Original languageEnglish
Article number1304
JournalPharmaceuticals
Volume14
Issue number12
DOIs
Publication statusPublished - Dec 2021

Keywords

  • Cardiac variant
  • Fabry disease
  • GLA
  • Hypertrophic cardiomyopathy
  • Kidney transplant
  • Late-onset phenotype
  • Migalastat
  • N215S

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Migalastat treatment in a kidney-transplanted patient with fabry disease and n215s mutation: The first case report'. Together they form a unique fingerprint.

Cite this